ALRN vs. PDSB, UBX, CPIX, NKTR, MRSN, XOMA, NATR, XERS, MGNX, and EPIX
Should you be buying Aileron Therapeutics stock or one of its competitors? The main competitors of Aileron Therapeutics include PDS Biotechnology (PDSB), Unity Biotechnology (UBX), Cumberland Pharmaceuticals (CPIX), Nektar Therapeutics (NKTR), Mersana Therapeutics (MRSN), XOMA (XOMA), Nature's Sunshine Products (NATR), Xeris Biopharma (XERS), MacroGenics (MGNX), and ESSA Pharma (EPIX). These companies are all part of the "medical" sector.
PDS Biotechnology (NASDAQ:PDSB) and Aileron Therapeutics (NASDAQ:ALRN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends, valuation, community ranking and media sentiment.
PDS Biotechnology is trading at a lower price-to-earnings ratio than Aileron Therapeutics, indicating that it is currently the more affordable of the two stocks.
26.8% of PDS Biotechnology shares are held by institutional investors. Comparatively, 90.9% of Aileron Therapeutics shares are held by institutional investors. 10.0% of PDS Biotechnology shares are held by company insiders. Comparatively, 5.6% of Aileron Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
In the previous week, Aileron Therapeutics had 3 more articles in the media than PDS Biotechnology. MarketBeat recorded 5 mentions for Aileron Therapeutics and 2 mentions for PDS Biotechnology. Aileron Therapeutics' average media sentiment score of 1.88 beat PDS Biotechnology's score of 0.33 indicating that PDS Biotechnology is being referred to more favorably in the media.
PDS Biotechnology has a beta of 1.75, indicating that its stock price is 75% more volatile than the S&P 500. Comparatively, Aileron Therapeutics has a beta of 2.32, indicating that its stock price is 132% more volatile than the S&P 500.
PDS Biotechnology's return on equity of -95.55% beat Aileron Therapeutics' return on equity.
Aileron Therapeutics received 152 more outperform votes than PDS Biotechnology when rated by MarketBeat users. However, 67.42% of users gave PDS Biotechnology an outperform vote while only 66.88% of users gave Aileron Therapeutics an outperform vote.
PDS Biotechnology presently has a consensus target price of $17.33, suggesting a potential upside of 493.61%. Aileron Therapeutics has a consensus target price of $19.00, suggesting a potential upside of 497.48%. Given PDS Biotechnology's higher probable upside, analysts clearly believe Aileron Therapeutics is more favorable than PDS Biotechnology.
Summary
Aileron Therapeutics beats PDS Biotechnology on 9 of the 14 factors compared between the two stocks.
Get Aileron Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALRN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ALRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aileron Therapeutics Competitors List
Related Companies and Tools
